期刊
EUROPEAN JOURNAL OF CANCER
卷 37, 期 13, 页码 1617-1623出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0959-8049(01)00169-1
关键词
anaemia; non-platinum chemotherapy; risk factors; epoetin alfa; erythropoietin
类别
A 2-year retrospective chart survey of 1064 patients with colorectal, breast, lung or ovarian cancer, Hodgkin's disease, or non-Hodgkin's lymphoma was conducted at 24 centres in France to determine the prevalence of anaemia (haemoglobin (Hb) levels less than or equal to 120 g/l) and need for transfusion in patients who received non-platinum-based chemotherapy for more than three cycles or 3 months. Baseline Hb levels documented anaemia in 37.1 % of patients (all tumour types). By cycle 3, the prevalence of anemia increased to 54.1 % of patients and remained over 50 % at cycle 4. At some time during chemotherapy 14.5 % of patients were transfused. Predictive risk factors for anaemia requiring transfusion included low baseline Hb, decrease in Hb during the first month of chemotherapy, primary tumour site, prior blood transfusions and duration of chemotherapy. By early identification of patients at the highest risk of developing anaemia, interventions such as epoetin alfa can be employed to reduce or eliminate the need for transfusions. (C) 2001 Elsevier Science Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据